European Journal of Surgical Oncology
Volume 34, Issue 12 , Pages 1316-1321 , December 2008

Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment

  • M. Kornmann

      Affiliations

    • Clinic of General, Visceral, and Transplantation Surgery, University of Ulm, Steinhoevelstrasse 9, 89075 Ulm, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 731 500 53511; fax: +49 731 500 53557.
    • ,
  • A. Formentini

      Affiliations

    • Clinic of General, Visceral, and Transplantation Surgery, University of Ulm, Steinhoevelstrasse 9, 89075 Ulm, Germany
    • ,
  • C. Ette

      Affiliations

    • Clinic of General, Visceral, and Transplantation Surgery, University of Ulm, Steinhoevelstrasse 9, 89075 Ulm, Germany
    • ,
  • D. Henne-Bruns

      Affiliations

    • Clinic of General, Visceral, and Transplantation Surgery, University of Ulm, Steinhoevelstrasse 9, 89075 Ulm, Germany
    • ,
  • M. Kron

      Affiliations

    • Institute of Biometrics, University of Ulm, Steinhoevelstrasse 9, 89075 Ulm, Germany
    • ,
  • S. Sander

      Affiliations

    • Institute of Biometrics, University of Ulm, Steinhoevelstrasse 9, 89075 Ulm, Germany
    • ,
  • W. Baumann

      Affiliations

    • Study Group Oncology of Gastrointestinal Tumors (FOGT), Asklepios Paulinen Klinik, Geisenheimer Strasse 10, 65187 Wiesbaden, Germany
    • ,
  • E.-D. Kreuser

      Affiliations

    • Study Group Oncology of Gastrointestinal Tumors (FOGT), Asklepios Paulinen Klinik, Geisenheimer Strasse 10, 65187 Wiesbaden, Germany
    • ,
  • L. Staib

      Affiliations

    • Study Group Oncology of Gastrointestinal Tumors (FOGT), Asklepios Paulinen Klinik, Geisenheimer Strasse 10, 65187 Wiesbaden, Germany
    • ,
  • K.H. Link

      Affiliations

    • Study Group Oncology of Gastrointestinal Tumors (FOGT), Asklepios Paulinen Klinik, Geisenheimer Strasse 10, 65187 Wiesbaden, Germany

,Accepted 18 January 2008.

References 

  1. Benson AB. New approaches to the adjuvant therapy of colon cancer. Oncologist. 2006;11:973–980
  2. Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–3419
  3. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–2704
  4. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351
  5. de Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C. Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol. 2007;34:S37–S40
  6. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol. 2004;22:1797–1806
  7. Link KH, Kornmann M, Staib L, et al. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU+levamisole with folinic acid or with interferon-alpha. Ann Surg. 2005;242:178–187
  8. Kolonkarzinom Junginger T. In:  Deutsche Krebsgesellschaft EV editors. Kurzgefasste interdisziplinäre Leitlinien 2002. Diagnostik und Therapie maligner Erkrankungen. Munich: W. Zuckschwerd-Verlag; 2002;p. 160–171
  9. Staib L, Link KH, Beger HG. Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1. J Gastrointest Surg. 2001;5:275–281
  10. World Health Organization . Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 894. World Health Organization; 2000;1–253
  11. Wittekind C, Wagner G. TNM classification of malignant tumors. 5th ed.. Berlin: Springer; 1997;
  12. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–1425
  13. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg. 2002;236:416–421
  14. Prandi M, Lionetto R, Bini A, et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg. 2002;235:458–463
  15. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24:2368–2375
  16. Rabeneck L, Davila JA, Thompson M, El-Serag HB. Surgical volume and long-term survival following surgery for colorectal cancer in the Veterans Affairs Health-Care System. Am J Gastroenterol. 2004;99:668–675
  17. Meyerhardt JA, Catalano PJ, Schrag D, et al. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med. 2003;139:649–657
  18. Ptok H, Marusch F, Kuhn R, et al. Influence of hospital volume on the frequency of abdominoperineal resections and long-term oncological outcomes in low rectal cancer. Eur J Surg Oncol. 2007;33:854–861
  19. Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98:484–495
  20. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98:1647–1654
  21. Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25:4707–4713
  22. Haller DG, Catalano PJ, MacDonald JS, et al. Fluorouracil (FU), Leucovorin (LV) and Levamisole (LEV) adjuvant therapy for colon cancer: five year final report of INT-0089. Proc Am Soc Clin Oncol. 1998;17:256
  23. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16:295–300

PII: S0748-7983(08)00035-8

doi: 10.1016/j.ejso.2008.01.019

European Journal of Surgical Oncology
Volume 34, Issue 12 , Pages 1316-1321 , December 2008

Article Tools

* Image Usage & Resolution